FBR Capital Maintains a 'Market Perform' on Amedisys (AMED); Focused on the Current Book of Business
Tweet Send to a Friend
FBR Capital maintains a 'Market Perform' rating on Amedisys (NASDAQ: AMED), raises PT from $27 to $31.
FBR analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
FBR analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
